Fractyl Health (NASDAQ:GUTS) Receives "Sell (E+)" Rating from Weiss Ratings

Key Points

• Fractyl Health (NASDAQ:GUTS) received a "Sell (E+)" rating from Weiss Ratings, indicating a bearish outlook on the stock.
• Despite the negative rating, four other analysts have given Fractyl Health a "Buy" rating, with a current average price target of $6.90.
• The company reported a loss of ($0.53) earnings per share, missing consensus estimates by ($0.16), and analysts predict it will post -1.61 EPS for the fiscal year.

Fractyl Health (NASDAQ:GUTS - Get Free Report)'s stock had its "sell (e+)" rating reiterated by research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Other equities analysts also recently issued research reports about the stock. LADENBURG THALM/SH SH initiated coverage on shares of Fractyl Health in a research report on Thursday, August 28th. They set a "buy" rating and a $3.60 price objective for the company. HC Wainwright cut their price objective on shares of Fractyl Health from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, September 26th. Finally, Canaccord Genuity Group cut their price objective on shares of Fractyl Health from $12.00 to $6.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $6.90.

Fractyl Health Trading Up 2.2%

Shares of GUTS stock opened at $1.40 on Wednesday. The company has a debt-to-equity ratio of 4.61, a quick ratio of 1.22 and a current ratio of 1.22. The stock has a market capitalization of $70.41 million, a P/E ratio of -0.68 and a beta of 2.27. The company has a 50 day moving average price of $1.14 and a 200 day moving average price of $1.44. Fractyl Health has a fifty-two week low of $0.83 and a fifty-two week high of $3.48.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.16). Equities research analysts predict that Fractyl Health will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Several hedge funds have recently modified their holdings of the company. General Catalyst Group Management LLC acquired a new stake in shares of Fractyl Health during the 2nd quarter worth about $7,912,000. Woodline Partners LP boosted its position in shares of Fractyl Health by 47.2% in the first quarter. Woodline Partners LP now owns 516,921 shares of the company's stock worth $615,000 after acquiring an additional 165,786 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Fractyl Health in the second quarter worth approximately $181,000. Qube Research & Technologies Ltd acquired a new stake in shares of Fractyl Health in the second quarter worth approximately $129,000. Finally, Nuveen LLC acquired a new stake in shares of Fractyl Health in the first quarter worth approximately $87,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.